Michael E. Berens, Ph.D.
Deputy Director, TGen Research Resources
Director, Cancer & Cell Biology Division
Professor, Brain Tumor Unit
Translational Genomics Research Institute
In addition to his roles as Deputy Director for Research Resources at TGen, Dr. Berens serves as Director of the Cancer and Cell Biology Division and Professor in the Brain Tumor Unit. Dr. Berens’ academic career has included appointments at the University of Zurich, the Bowman Gray School of Medicine of Wake Forest University, the University of California at San Francisco, and the Barrow Neurological Institute. At BNI, he served for 12 years as Senior Investigator and Director of Neurology Research. He currently leads a translational research program in brain tumors that includes preclinical therapy development, novel treatment target discovery, and the study of malignant cell motility; early stage clinical trials in patients with malignant glioma, informed by genomic and proteomic profiling (theranostic biomarkers), demand major portions of his attention. His research program includes collaborations with Barrow Neurological Institute, Mayo Clinic, multi-institutional consortia and laboratories in Seoul, Tokyo, Sydney and Bergen (Norway). Dr. Berens current research is funded by the National Institutes of Health and private medical Foundations, including the Ben & Catherine Ivy Foundation. Dr. Berens holds four patents, and is founder of two for-profit ventures: Creative Scientific Methods Inc., and Avolix Pharmaceuticals, Inc. He serves on editorial boards for scientific journals and committees that support governmental agencies, professional societies, and non-profit organizations. He is also active in the technology and public policy sectors, and is a past Chairman of the Arizona Technology Council. Dr. Berens received his Ph.D. from the University of Arizona.